Clinical Trials on Stage IV Fallopian Tube Cancer

Total 5056 results

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Active, not recruiting

Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer (GOGER-01)

Ovarian Cancer | Fallopian Tube Carcinoma | Peritoneal Carcinoma

Italy
Pfizer

Completed

Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
The University of The West Indies

Unknown

Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer

Stage IV Breast Cancer | Stage IV Prostate Cancer | Stage IV Colon Cancer | Stage IV Cancer of the Cervix

Jamaica
Imunon

Active, not recruiting

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) (OVATION 2)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States, Canada
Amgen

Completed

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States, France, Italy, Spain, United Kingdom, Belgium, Canada, Poland, Switzerland, Korea, Republic of, Russian Federation, Hong Kong, Portugal, South Africa, Israel, Romania, Bulgaria, Greece, Australia, Sweden, Japan, Latvia and more
New Mexico Cancer Care Alliance

Active, not recruiting

Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI); Massachusetts General Hospital; Dana-Farber... and other collaborators

Active, not recruiting

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States
zr Pharma & GmbH
Foundation Medicine; Myriad Genetics, Inc.

Completed

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) (ARIEL3)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Spain, Belgium, Australia, Israel, Germany, France, United Kingdom, Italy, Canada, New Zealand
Masonic Cancer Center, University of Minnesota

Terminated

Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Mount Vernon Cancer Centre at Mount Vernon Hospital

Unknown

CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United Kingdom
K-Group, Beta, Inc., a wholly owned subsidiary...

Recruiting

A Study of ZN-c3 in Patients With Ovarian Cancer

Fallopian Tube Cancer | Solid Tumor | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Australia, Bulgaria, Bosnia and Herzegovina, Georgia, Korea, Republic of, Serbia
Yale University
National Cancer Institute (NCI)

Terminated

Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Uppsala University Hospital
Norrlands Universitetssjukhus, Umea, Sweden

Recruiting

Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test (FOLL-OV)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

Sweden
Lee's Pharmaceutical Limited

Not yet recruiting

A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer
Geoff Hall
National Health Service, United Kingdom

Completed

LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer | Gynaecological Malignancy

United Kingdom
Masonic Cancer Center, University of Minnesota

Completed

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Sarcoma | Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Thromboembolism | Vulvar Cancer | Endometrial Cancer | Vaginal Cancer

United States
Aesculap AG
B.Braun Surgical SA

Recruiting

Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy (BARHYSTER)

Cervical Cancer | Endometriosis | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Uterine Prolapse | Uterine Cancer | Abnormal Uterine Bleeding

Germany, Spain
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Mucinous... and other conditions

United States, Korea, Republic of, Japan
University Health Network, Toronto
GlaxoSmithKline

Recruiting

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Cancer | High Grade Endometrioid Cancer

Canada
Cure Cancer Worldwide Corporation

Unknown

Observational Study of Survival Outcomes of Stage IV Cancer Patients

Survival | Stage IV Cancer (Solid Tumors Only)

China
Morphotek

Completed

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Germany
Green3Bio, Inc.

Suspended

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

Ovarian Tumors

United States
Masonic Cancer Center, University of Minnesota

Terminated

WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinoma

United States
MEI Pharma, Inc.

Completed

OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer (OVATURE)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Spain, Belgium, United Kingdom, Australia, Italy, Poland
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma

United States
Case Comprehensive Cancer Center

Completed

Debulking Surgery in Ovarian Cancer (MIID-SOC)

Malignant Neoplasm of Ovary | Malignant Neoplasm of Fallopian Tube | Malignant Neoplasm of Peritoneum

United States
Mural Oncology, Inc
Merck Sharp & Dohme LLC

Recruiting

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (ARTISTRY-7)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer

United States, Spain, Korea, Republic of, Taiwan, Canada, Israel, France, United Kingdom, Germany, Belgium, Czechia, Singapore, Australia, Austria, Italy
Syndax Pharmaceuticals
Pfizer; Merck KGaA, Darmstadt, Germany

Completed

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States
Imunon

Completed

Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Nordic Society of Gynaecological Oncology - Clinical...

Recruiting

Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype (HERO)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Denmark
AGO Study Group
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Recruiting

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

Germany
Shanghai Gynecologic Oncology Group
Zhejiang Cancer Hospital; Sun Yat-sen University; Fudan University; Shanghai Jiao...

Recruiting

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Ovarian Cancer Recurrent

China
Takeda

Completed

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Japan
National Cancer Institute (NCI)

Completed

Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Primary Peritoneal Neoplasms

United States
Ronald Buckanovich
Genentech, Inc.

Recruiting

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

PARP Inhibitor | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Hedgehog Inhibitor

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Recurrent Prostate Cancer | Fallopian Tube Cancer | Bone Metastases | Lung Metastases | Stage III Renal Cell Cancer | Liver Metastases | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Inflammatory Breast Cancer | Metastatic Transitional Cell Cancer of the... and other conditions

United States
Vanderbilt-Ingram Cancer Center
AstraZeneca; Syndax Pharmaceuticals

Terminated

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Fallopian Tube Cancer | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Recurrent Endometrial Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Primary Peritoneal... and other conditions

United States
pharmaand GmbH

Completed

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer | Other Solid Tumor | Metastatic Castration-Resistant Prostate Cancer

Israel, Italy, Canada, Russian Federation, United Kingdom, Poland
University Health Network, Toronto

Active, not recruiting

"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Ovarian Cancer | Recurrent | Platinum-resistant

Canada
AA Secord
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer | Gynecologic Neoplasms | Uterine Endometrial Cancer

United States
University of Southern Denmark
Ministry of the Interior and Health, Denmark; Danish Clinical Intervention...

Completed

Pharmacogenomics of Paclitaxel in Ovarian Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms

Denmark, Sweden
National Cancer Institute (NCI)

Completed

Phase II ABT-888 With Cyclophosphamide

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Triple-Negative Breast Cancer | Serous Carcinoma Cancer

United States, Canada
Wake Forest University Health Sciences

Terminated

Effects of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer

Head and Neck Cancer | Stage I Laryngeal Cancer | Stage II Laryngeal Cancer | Stage I Hypopharyngeal Cancer | Stage I Oropharyngeal Cancer | Stage II Hypopharyngeal Cancer | Stage II Oropharyngeal Cancer | Stage III Hypopharyngeal Cancer | Stage III Laryngeal Cancer | Stage III Oropharyngeal Cancer | Stage... and other conditions

United States
Millennium Pharmaceuticals, Inc.

Completed

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Fallopian Tube Cancer | Breast Carcinoma | Ovarian Carcinoma | Peritoneal Cancer

United States
Hansoh BioMedical R&D Company

Recruiting

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cancer

China
ARCAGY/ GINECO GROUP
AstraZeneca

Completed

Genomic BRCA and Extensive ovArian Cancer Testing (GREAT)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

France
ImmunoGen, Inc.

Active, not recruiting

IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Ovarian Cancer

United States, United Kingdom, Belgium, Spain, Canada, Georgia
Canadian Cancer Trials Group
National Cancer Institute (NCI); Cancer Research UK; Grupo Español de Investigación... and other collaborators

Completed

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer | Metastatic Cancer

Canada, Spain, United States, United Kingdom
K-Group, Beta, Inc., a wholly owned subsidiary...

Recruiting

A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Carcinoma

United States, France

Clinical Trials on Stage IV Fallopian Tube Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations